Sales Revenue
FY25 — $185.3M
↑ +9.7% YoY
Source: Cenversa Annual Reports · in AUD millions
Results Driven
Cenversa is all about results
Cenversa is a performance based company and our results clearly demonstrate the quality of the group's executives and dedicated staff to achieving results year on year. Since becoming an unlisted public company in 2013, Cenversa has experienced continued, exceptional growth.
$185.3M
Sales Revenue FY25
+9.7%
$9.46M
Underlying EBITDA FY25
+4.6%
Revenue Breakdown
A diversified business
FY2025 $6.7M
- Wholesale Activities 39.1%
- Other Activities 60.9%
Financial Performance
FY25 results at a glance
Underlying EBITDA*
FY25 — $9.46M
↑ +4.6% YoY
2021 2022 2023 2024 2025
* Earnings before tax, depreciation, amortisation and acquisition costs associated with veterinary practices.
Financial Performance Overview
Year on Year overview
Overview 2024-2025
| Key Indicator | FY2025 | FY2024 | % Change on previous Year |
|---|---|---|---|
| Sales Revenue | $185.30m | $168.85m | 9.74% |
| Gross Profit | $49.79m | $47.34m | 5.18% |
| Net Profit Before Tax | $2.09m | $1.70m | 23.53% |
| Underlying EBITDA* | $9.46m | $9.04m | 4.63% |
| Net Assets | $25.29m | $24.58m | 2.90% |
* All values shown rounded to two decimal places. Underlying EBITDA — Earnings before tax, depreciation and amortisation, and acquisition costs associated with acquisitions and legal costs associated with proceedings on behalf of the company.